“Pancreatic ductal adenocarcinoma (PDAC) has a higher incidence and worse outcomes among black patients than white patients, potentially owing to a combination of socioeconomic, biological, and treatment differences,” explained Danielle R. Heller, MD, Section of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, and colleagues, who sought to find out whether treatment inequity contributes to this disparity in survival. Read more . . . .